Granules India Ltd (GRANULES):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Granules India Ltd (GRANULES) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10153
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Granules India Ltd (Granules) is a pharmaceutical manufacturing company, which carries out the research, development and manufacture of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs). The company manufactures Paracetomol, Ibuprofen, Metformin, Guaifenesin and Methocarbamol. It has premier facilities for the manufacture of APIs, PFIs and FDs. With offices in India, the US, the UK, China and Colombia, the company offers products and solutions to companies across the world. Granules also provides contract research and manufacturing services. Its key clients include leading generic and branded pharmaceutical companies. Granules is headquartered in Hyderabad, Telangana, India.

Granules India Ltd (GRANULES) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Granules India Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Granules India Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Granules Pharma Enters into Licensing Agreement with USpharma Windlas 11
Equity Offering 12
Granules India Raises USD77.3 Million in Qualified Institutions Placement of Equity Shares 12
Acquisition 13
Granules Pharma to Acquire 12.5% Stake in Uspharma 13
Granules India Acquires Auctus Pharma for USD19 Million 14
Granules India Ltd – Key Competitors 15
Granules India Ltd – Key Employees 16
Granules India Ltd – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Recent Developments 18
Financial Announcements 18
May 24, 2018: Granules India’s Total Income increases by 18% to INR 1,703 Cr 18
Feb 08, 2018: Granules India’s Revenue from operation increases by 14% to INR 411 Cr 19
Nov 09, 2017: Granules India’s Revenue from operation increases by 8% to INR 393 Cr 20
Aug 14, 2017: Granules India Reported Its First Quarter Financial Results 2017 21
May 11, 2017: Granules India’s Revenue increases 4% to Rs. 1,435 Cr.; Net Profit surges 34% to Rs. 165 Cr 22
Jan 28, 2017: Granules India’s Net Profit rises by 34% to Rs. 39 Cr 23
Legal and Regulatory 24
Mar 26, 2018: Granules India’s Gagillapur and Jeedimetla facilities complete US FDA inspection 24
Feb 28, 2018: Granules India’s Chantilly facility received EIR from USFDA 25
Oct 06, 2017: Receipt of establishment report by Granules OmniChem facility from US FDA 26
Feb 03, 2017: Granules India’s Gagillapur facility completed INFARMED reinspection 27
Jan 06, 2017: Granules India’s Gagillapur Facility Completed INFARMED Inspection 28
Other Significant Developments 29
Aug 16, 2017: Granules India Reports Establishment Inspection Report (EIR) From US FDA-Reg. 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
Granules India Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Granules India Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Granules Pharma Enters into Licensing Agreement with USpharma Windlas 11
Granules India Raises USD77.3 Million in Qualified Institutions Placement of Equity Shares 12
Granules Pharma to Acquire 12.5% Stake in Uspharma 13
Granules India Acquires Auctus Pharma for USD19 Million 14
Granules India Ltd, Key Competitors 15
Granules India Ltd, Key Employees 16
Granules India Ltd, Subsidiaries 17
Granules India Ltd, Joint Venture 17

List of Figures
Granules India Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Granules India Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Granules India Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Granules India Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Granules India Ltd (GRANULES):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • MediaTek Inc.:企業の戦略・SWOT・財務情報
    MediaTek Inc. - Strategy, SWOT and Corporate Finance Report Summary MediaTek Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Gedeon Richter Plc:企業の戦略・SWOT・財務情報
    Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report Summary Gedeon Richter Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Dai Nippon Printing Co Ltd (7912):企業の財務・戦略的SWOT分析
    Dai Nippon Printing Co Ltd (7912) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Tech Mahindra Limited (TECHM):企業の財務・戦略的SWOT分析
    Tech Mahindra Limited (TECHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Arrow Electronics Inc (ARW):企業の財務・戦略的SWOT分析
    Arrow Electronics Inc (ARW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Provenance Biopharmaceuticals Corp-製薬・医療分野:企業M&A・提携分析
    Summary Provenance Biopharmaceuticals Corp (Provenance) is a biotechnology company that develops various novel immunotherapeutic drugs to treat cancer and other serious, life-threatening diseases. The company offers cancer drugs based on antibodies which include avastin, erbitux, hercepton, and ritu …
  • Guangzhou R&F Properties Co Ltd:企業の戦略・SWOT・財務情報
    Guangzhou R&F Properties Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Guangzhou R&F Properties Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • National Gypsum Co:企業の戦略・SWOT・財務分析
    National Gypsum Co - Strategy, SWOT and Corporate Finance Report Summary National Gypsum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • HSH Nordbank AG:企業の戦略・SWOT・財務情報
    HSH Nordbank AG - Strategy, SWOT and Corporate Finance Report Summary HSH Nordbank AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Mitel Networks Corporation:企業のM&A・事業提携・投資動向
    Mitel Networks Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mitel Networks Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Havells India Ltd (HAVELLS):企業の財務・戦略的SWOT分析
    Havells India Ltd (HAVELLS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Taghleef Industries L.L.C.
    Taghleef Industries L.L.C. - Strategy, SWOT and Corporate Finance Report Summary Taghleef Industries L.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Varta Microbattery GmbH:企業の戦略的SWOT分析
    Varta Microbattery GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Thomson Reuters Corporation:企業の戦略・SWOT・財務情報
    Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report Summary Thomson Reuters Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Celltrion Inc (068270):企業の財務・戦略的SWOT分析
    Celltrion Inc (068270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Wesfarmers Limited:戦略・SWOT・企業財務分析
    Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report Summary Wesfarmers Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Kyushu Financial Group Inc (7180):企業の財務・戦略的SWOT分析
    Kyushu Financial Group Inc (7180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • SMCP S.A.S (SMCP):企業の財務・戦略的SWOT分析
    SMCP S.A.S (SMCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CMA CGM SA:企業の戦略・SWOT・財務情報
    CMA CGM SA - Strategy, SWOT and Corporate Finance Report Summary CMA CGM SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Haplogen GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Haplogen GmbH (Haplogen) is a biopharmaceutical company that improves human health by fighting against infectious diseases such as common cold, dengue fever, influenza and hepatitis C. The company utilizes its proprietary genetics technology platform to identify novel pathogen host factors a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆